cryptocurrency advice Top Reviews

The total investment scale of Haiyouwei's factory in the United States may reach 10 million US dollars. According to Haiyouwei Science and Technology, on December 11th, Haiyouwei announced that it planned to set up a subsidiary in the United States to implement the polymer special membrane project. This project is a deepening cooperation between Haiyouwei and its industry partners on the basis of strategic and technical cooperation in the United States. It is an important measure to achieve the localized production and market-oriented extension of the company's photovoltaic packaging film in the American market. It is estimated that the total investment will not exceed 10 million US dollars.FTSE China A50 index futures rose 1%.The trading of traditional Chinese medicine has increased the daily limit of Panlong Pharmaceutical, the trading of traditional Chinese medicine has increased, Panlong Pharmaceutical has increased its daily limit, Xiangxue Pharmaceutical has increased by over 9%, and Kunyao Group, Weikang Pharmaceutical, Huasen Pharmaceutical and Xinguang Pharmaceutical have followed suit.

The bauxite of the Guinea project of Tianshan Aluminum Group was shipped for the first time. According to the news of Tianshan Aluminum Group, on the afternoon of December 11th, local time in Guinea, Zeng Chaolin, the chairman of the company, attended and presided over the first shipment ceremony of the bauxite of Guinea project. This inaugural ceremony marks that the whole chain of the project has entered the operation stage. Subsequently, the company will increase infrastructure investment and mining scale, and gradually increase production capacity and transportation capacity. It is expected that the bauxite self-sufficiency rate will be 100% within two years, ensuring the company to obtain stable and low-cost bauxite resources and continuously maintain the competitive advantage of the integrated industrial chain.The Nikkei 225 index closed at 39,881.10 points in early trading, up 1.29%.The retail sector rose and strengthened, and more than 10 stocks such as Yonghui Supermarket rose and strengthened. More than 10 stocks such as Yonghui Supermarket, Maoye Commercial, Zhongbai Group, Nanning Department Store, Youhao Group and Dongbai Group rose and strengthened.

Runhe Software and other 300 million yuan set up a venture capital fund partnership. The enterprise search APP shows that Yuanshi (Changzhou) venture capital fund partnership (limited partnership) was established recently with a capital contribution of 300 million yuan, and its business scope includes: venture capital (limited investment in unlisted enterprises); Engage in equity investment, investment management, asset management and other activities with private equity funds. Enterprise equity penetration shows that the enterprise is jointly held by Runhe Software.The retail sector rose and strengthened, and more than 10 stocks such as Yonghui Supermarket rose and strengthened. More than 10 stocks such as Yonghui Supermarket, Maoye Commercial, Zhongbai Group, Nanning Department Store, Youhao Group and Dongbai Group rose and strengthened.Genting Xinyao: The first prescription of itramod in Macau, China officially benefited Asian patients. Genting Xinyao announced that its first prescription of itramod was made in Jinghu Hospital in Macau, China on December 11th, which was the first prescription made by itramod after it was approved in Genting Xinyao Asia Authorized Zone, marking that this heavy product in the field of autoimmune diseases officially began to benefit Asian patients. Luo Yongqing, CEO of Genting Xinyao, said that the arrival of the first prescription of Ithmod in China and Macau was another milestone in the commercialization of Genting Xinyao. By 2030, the number of patients with ulcerative colitis in China is expected to more than double that in 2019, reaching about 1 million. There is a huge unmet demand for innovative therapies. Following the approval in Macau in April this year, Iturmod, as the third commercial new drug of Genting Xinyao, will bring new treatment options to more patients with ulcerative colitis.